Orgenesis Meets With the Paul-Ehrlich Institute
11/19/2012 9:45:34 AM
WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that it has recently held its first scientific meeting with the Paul-Ehrlich Institute (“PEI”), completing another important step toward initiating advanced stage trials of the Company’s technology. The PEI is an agency of the German Federal Ministry of Health, responsible for all regulatory issues related to the development of innovative therapies and advanced medicinal products in its home country. The PEI also plays an important role in various committees, working parties and expert groups at the European Medicines Agency (“EMA”).
comments powered by